Steve Seedhouse
Stock Analyst at Cantor Fitzgerald
(1.80)
# 3,254
Out of 5,179 analysts
20
Total ratings
36.84%
Success rate
-7.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRZN Surrozen | Reiterates: Overweight | $40 | $28.90 | +38.41% | 2 | Mar 24, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Overweight | $35 → $31 | $16.97 | +82.68% | 3 | Mar 18, 2026 | |
| KRRO Korro Bio | Maintains: Overweight | $21 → $22 | $10.40 | +111.54% | 3 | Mar 13, 2026 | |
| HROW Harrow | Maintains: Overweight | $94 → $91 | $33.83 | +168.99% | 2 | Mar 4, 2026 | |
| BLTE Belite Bio | Maintains: Overweight | $200 → $266 | $152.07 | +74.92% | 2 | Mar 3, 2026 | |
| WVE Wave Life Sciences | Maintains: Overweight | $34 → $41 | $6.37 | +544.15% | 2 | Feb 5, 2026 | |
| XNCR Xencor | Maintains: Overweight | $40 → $42 | $11.42 | +267.78% | 2 | Nov 6, 2025 | |
| INVA Innoviva | Maintains: Overweight | $29 → $31 | $22.66 | +36.80% | 2 | Nov 6, 2025 | |
| CAMP Camp4 Therapeutics | Initiates: Overweight | $7 | $4.31 | +62.41% | 1 | Oct 2, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Overweight | $52 | $3.17 | +1,540.38% | 1 | Jul 11, 2025 |
Surrozen
Mar 24, 2026
Reiterates: Overweight
Price Target: $40
Current: $28.90
Upside: +38.41%
Apellis Pharmaceuticals
Mar 18, 2026
Maintains: Overweight
Price Target: $35 → $31
Current: $16.97
Upside: +82.68%
Korro Bio
Mar 13, 2026
Maintains: Overweight
Price Target: $21 → $22
Current: $10.40
Upside: +111.54%
Harrow
Mar 4, 2026
Maintains: Overweight
Price Target: $94 → $91
Current: $33.83
Upside: +168.99%
Belite Bio
Mar 3, 2026
Maintains: Overweight
Price Target: $200 → $266
Current: $152.07
Upside: +74.92%
Wave Life Sciences
Feb 5, 2026
Maintains: Overweight
Price Target: $34 → $41
Current: $6.37
Upside: +544.15%
Xencor
Nov 6, 2025
Maintains: Overweight
Price Target: $40 → $42
Current: $11.42
Upside: +267.78%
Innoviva
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $31
Current: $22.66
Upside: +36.80%
Camp4 Therapeutics
Oct 2, 2025
Initiates: Overweight
Price Target: $7
Current: $4.31
Upside: +62.41%
Tvardi Therapeutics
Jul 11, 2025
Initiates: Overweight
Price Target: $52
Current: $3.17
Upside: +1,540.38%